A recent study highlights a previously unknown function of the TDP-43 protein in nerve cells that may contribute to the progression of amyotrophic lateral sclerosis (ALS). The finding adds a new layer of knowledge that could help to better understand the mechanisms involved in ALS development and progression. TDP-43 protein…
News
The National Institute of Neurological Disorders and Stroke (NINDS) has awarded Aquinnah Pharmaceuticals $3.4 million to continue to develop and advance potential therapies to treat amyotrophic lateral sclerosis (ALS). This NINDS grant is the second given to Aquinnah to help support its novel approach for the treatment of…
Online health forums offers patients with chronic diseases a way to share experiences and develop connections with others in a similar situation — gaining access to a community that can provide both empathy and support, a study shows. How empathy might develop in online exchanges was the focus of the…
The National Institute of Neurological Disorders and Stroke (NINDS) awarded $3.7 million to AcuraStem to support the development of a small molecule drug to treat C9orf72 gene-related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The Small Business Innovation Research (SBIR) fast-track grant (R44NS105156) will promote the development…
Patients with amyotrophic lateral sclerosis (ALS) show alterations in the activity of their masticatory (jaw) muscles, impairing their ability to chew, according to the results of a small study. The study, “Alterations in the stomatognathic system due to amyotrophic lateral sclerosis,” was published in the Journal of Applied…
A university-led clinical trial will assess the therapeutic effect of Celestone (betamethasone) injections in amyotrophic lateral sclerosis (ALS) patients with mutations in the FUS gene — a particular genetic type of ALS that seems to be clustered in a nearby region. Inherited ALS is rare and only affects up…
Flex Pharma announced that it is stopping Phase 2 clinical trials of its investigational compound to ease muscle cramps, FLX-787, in patients with amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (CMT). The company’s decision was based on tolerability concerns in each study with the oral disintegrating tablet formulation at 30…
Researchers have developed a personalized, non-invasive model that uses a set of characteristics, easily obtained at diagnosis, to predict survival in patients with amyotrophic lateral sclerosis (ALS). The study with that finding, “Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model,” was published…
Patients with amyotrophic lateral sclerosis (ALS) are at increased risk for having pressure sores (PrS), according to a recent study. This risk is especially high for women and young patients, the findings showed. The study “Risk of developing PrS in amyotrophic lateral sclerosis patients – a nationwide cohort…
Cognitive deficits associated with amyotrophic lateral sclerosis (ALS) are linked to a particular pattern of abnormal changes and altered blood flow in specific brain regions, a study shows. The study titled “Brain Structural and Perfusion Signature of Amyotrophic Lateral Sclerosis With Varying Levels of Cognitive Deficit” was…
Recent Posts
- A story of a family’s loss offers guidance amid my grief with ALS
- MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS
- Holding the line: Why I’d keep my ALS progression exactly as it is
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- MDA 2026: New ALS platform trial adds RT1999 to speed search for treatments